Fate Therapeutics, Inc.

Informe acción NasdaqGM:FATE

Capitalización de mercado: US$291.4m

Fate Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Fate Therapeutics es Bob Valamehr , nombrado en Jan 2025, tiene una permanencia de 1.58 años. compensación anual total es $2.25M, compuesta por 26.7% salario y 73.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.098% de las acciones de la empresa, por valor de $287.00K. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 7.1 años, respectivamente.

Información clave

Bob Valamehr

Chief Executive Officer (CEO)

US$2.2m

Compensación total

Porcentaje del salario del CEO26.68%
Permanencia del CEO1.6yrs
Participación del CEO0.1%
Permanencia media de la dirección1.6yrs
Promedio de permanencia en la Junta Directiva7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Jun 24

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Summary Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the stock. They’ve reported broader autoimmune data and are now planning RECLAIM-LN. Unfortunately, I think their recent removal from the Russell 3000 index could be a near-term headwind for the stock price itself. However, I don’t think this index removal will have a major impact on their underlying R&D progress with FT819. On balance, I still believe FATE offers good upside potential at these levels despite its inherent risks tied to RECLAIM-LN’s clinical data in the long run. Read the full article on Seeking Alpha
Artículo de análisis • Nov 25

Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Aug 08

Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

NasdaqGM:FATE 1 Year Share Price vs Fair Value Explore Fate Therapeutics's Fair Values from the Community and select...
Artículo de análisis • Apr 22

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 05

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline. The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”. Read the full article on Seeking Alpha
Artículo de análisis • Jan 06

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 20

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Summary Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. FT522 is also being explored in phase 1 trials for the treatment of patients with relapsed/refractory B-cell lymphoma and B-cell mediated autoimmune disorders. Read the full article on Seeking Alpha
Artículo de análisis • Aug 21

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders will have a reason to smile today, with the analysts making...
Artículo de análisis • Aug 11

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 29

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share. Read the full article on Seeking Alpha
Artículo de análisis • Apr 23

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...
Artículo de análisis • Feb 16

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Despite an already strong run, Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have been powering on, with a gain of 57...
Seeking Alpha • Jan 26

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article. The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential. Read the full article on Seeking Alpha
Artículo de análisis • Dec 19

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

The Fate Therapeutics, Inc. ( NASDAQ:FATE ) share price has done very well over the last month, posting an excellent...
Artículo de análisis • Sep 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Artículo de análisis • Jun 07

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4x Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be sending very bullish...
Artículo de análisis • May 08

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Shareholders in Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be thrilled to learn that the analysts have just delivered...
Artículo de análisis • Apr 17

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Jan 10

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bob Valamehr en comparación con los beneficios de Fate Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$130m

Dec 31 2025US$2mUS$600k

-US$136m

Sep 30 2025n/an/a

-US$156m

Jun 30 2025n/an/a

-US$172m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$4mUS$525k

-US$186m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$3mUS$500k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$3mUS$455k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$6mUS$430k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$2mUS$390k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$3mUS$375k

-US$98m

Compensación vs. Mercado: La compensación total de Bob($USD2.25M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.64M).

Compensación vs. Ingresos: La compensación de Bob ha sido consistente con los resultados de la empresa en el último año.

CEO

Bob Valamehr (49 yo)

1.6yrs
Permanencia
US$2,248,568
Compensación

Dr. Bahram Valamehr, also known as Bob, Ph D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and serves as its Director since January 2025 and was its President of Research...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Bahram Valamehr
President1.6yrsUS$2.25m0.098%
$ 287.0k
Kamal Adawi
CFO & Treasurerless than a yearUS$1.11m0%
$ 0
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary10.8yrsUS$1.11m0.54%
$ 1.6m
Jessica Francis
Senior Vice President of Human Resources & Operations1.6yrssin datossin datos
Martin Hosking
Head of Researchless than a yearsin datossin datos
Tunde Babalola
Senior Vice President of Technical Operations & Quality1.6yrssin datossin datos
Ryan Douglas
Senior Director of Investor Relations & Business Developmentless than a yearsin datossin datos
Andrew Henry
Senior Vice President of Clinical Operations2.6yrssin datossin datos
Yu Cai
Head of Intellectual Property & Assistant General Counsel1.6yrssin datossin datos
Kate Duvall
Corporate Controller1.3yrssin datossin datos
1.6yrs
Permanencia media
51yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de FATE no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Bahram Valamehr
President1.6yrsUS$2.25m0.098%
$ 287.0k
William Rastetter
Independent Chairman14.8yrsUS$142.98k0.55%
$ 1.6m
Robert Epstein
Independent Director12.4yrsUS$123.71k0.031%
$ 90.8k
Michael Lee
Independent Director8.1yrsUS$104.09k0.0097%
$ 28.3k
Laura Hamill
Independent Directorless than a yearsin datossin datos
Matthew Abernethy
Independent Director1.3yrsUS$151.61k0%
$ 0
Karin Jooss
Independent Director7.4yrsUS$118.96k0.0084%
$ 24.6k
Shefali Agarwal
Independent Director7.1yrsUS$115.09k0.0090%
$ 26.2k
Yuan Xu
Independent Director5yrsUS$111.52k0.0074%
$ 21.7k
7.1yrs
Permanencia media
58yo
Promedio de edad

Junta con experiencia: La junta directiva de FATE se considera experimentada (7.1 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/08/04 15:17
Precio de las acciones al final del día2026/08/04 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Fate Therapeutics, Inc. está cubierta por 25 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Jack AllenBaird
Tazeen AhmadBofA Global Research
Amanda MurphyBTIG